Megumi Aizawa‐Abe

2.7k total citations · 1 hit paper
25 papers, 2.1k citations indexed

About

Megumi Aizawa‐Abe is a scholar working on Endocrine and Autonomic Systems, Physiology and Epidemiology. According to data from OpenAlex, Megumi Aizawa‐Abe has authored 25 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Endocrine and Autonomic Systems, 10 papers in Physiology and 9 papers in Epidemiology. Recurrent topics in Megumi Aizawa‐Abe's work include Regulation of Appetite and Obesity (16 papers), Adipose Tissue and Metabolism (10 papers) and Biochemical Analysis and Sensing Techniques (9 papers). Megumi Aizawa‐Abe is often cited by papers focused on Regulation of Appetite and Obesity (16 papers), Adipose Tissue and Metabolism (10 papers) and Biochemical Analysis and Sensing Techniques (9 papers). Megumi Aizawa‐Abe collaborates with scholars based in Japan, United States and South Korea. Megumi Aizawa‐Abe's co-authors include Ken Ebihara, Yoshihiro Ogawa, Kazuwa Nakao, Kiminori Hosoda, Gen Inoue, Tatsuya Hayashi, Hiroaki Masuzaki, Mitsuyo Shintani, Fumiko Miyanaga and Noriko Satoh and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Megumi Aizawa‐Abe

25 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ghrelin, an Endogenous Growth Hormone Secretagogue, Is a Novel Orexigenic Peptide That Antagonizes Leptin Action Through the Activation of Hypothalamic Neuropeptide Y/Y1 Receptor Pathway

2001 690 citations Mitsuyo Shintani, Yoshihiro Ogawa et al. Diabetes profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Megumi Aizawa‐Abe Japan	16	1.5k	1.1k	875	592	332	25	2.1k
Teresa Priego Spain	28	687 0.5×	1.3k 1.2×	473 0.5×	444 0.8×	469 1.4×	71	2.2k
Fumiko Miyanaga Japan	9	880 0.6×	643 0.6×	552 0.6×	297 0.5×	259 0.8×	10	1.3k
Mário J. A. Saad Brazil	16	563 0.4×	745 0.7×	260 0.3×	500 0.8×	448 1.3×	27	1.7k
Juliana C. Moraes Brazil	16	580 0.4×	719 0.7×	276 0.3×	444 0.8×	339 1.0×	19	1.5k
Tomomi Shiiya Japan	13	1.6k 1.1×	984 0.9×	1.1k 1.2×	285 0.5×	84 0.3×	15	2.0k
Anne E. Evans United States	8	806 0.5×	618 0.6×	429 0.5×	333 0.6×	143 0.4×	11	1.4k
James L. Trevaskis United States	30	1.1k 0.8×	1.2k 1.2×	573 0.7×	933 1.6×	886 2.7×	60	3.2k
Kristy M. Heppner United States	21	672 0.5×	738 0.7×	338 0.4×	220 0.4×	424 1.3×	27	1.7k
Laura Oksanen Finland	16	767 0.5×	569 0.5×	444 0.5×	344 0.6×	261 0.8×	19	1.4k
Mitsuyo Shintani Japan	7	801 0.5×	568 0.5×	527 0.6×	213 0.4×	211 0.6×	10	1.1k

Countries citing papers authored by Megumi Aizawa‐Abe

Since Specialization

Citations

This map shows the geographic impact of Megumi Aizawa‐Abe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Megumi Aizawa‐Abe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Megumi Aizawa‐Abe more than expected).

Fields of papers citing papers by Megumi Aizawa‐Abe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Megumi Aizawa‐Abe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Megumi Aizawa‐Abe. The network helps show where Megumi Aizawa‐Abe may publish in the future.

Co-authorship network of co-authors of Megumi Aizawa‐Abe

This figure shows the co-authorship network connecting the top 25 collaborators of Megumi Aizawa‐Abe. A scholar is included among the top collaborators of Megumi Aizawa‐Abe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Megumi Aizawa‐Abe. Megumi Aizawa‐Abe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aizawa‐Abe, Megumi, et al.. (2023). Successful Treatment of Postprandial Hyperinsulinemic Hypoglycemia After Billroth-II Gastrojejunostomy Using Octreotide. JCEM Case Reports. 1(6). luad150–luad150. 1 indexed citations

Aizawa‐Abe, Megumi, et al.. (2022). Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver. Scientific Reports. 12(1). 449–449. 10 indexed citations

Yoshiji, Satoshi, Yukio Horikawa, Mayumi Enya, et al.. (2021). Identification of the first Japanese family with PDX1-MODY (MODY4): a novel PDX1 frameshift mutation, clinical characteristics, and implications. Zenodo (CERN European Organization for Nuclear Research). 1 indexed citations

Yoshiji, Satoshi, Yukio Horikawa, Mayumi Enya, et al.. (2021). First Japanese Family With PDX1-MODY (MODY4): A Novel PDX1 Frameshift Mutation, Clinical Characteristics, and Implications. Journal of the Endocrine Society. 6(1). bvab159–bvab159. 16 indexed citations

Goto, Tsuyoshi, Mariko Hirata, Yumeko Aoki, et al.. (2017). The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice. Journal of Biological Chemistry. 292(22). 9175–9190. 53 indexed citations

Ebihara, Ken, Megumi Aizawa‐Abe, Tomoji Mashimo, et al.. (2015). Seipin is necessary for normal brain development and spermatogenesis in addition to adipogenesis. Human Molecular Genetics. 24(15). 4238–4249. 40 indexed citations

Ebihara, Ken, Megumi Aizawa‐Abe, Makoto Nishio, et al.. (2014). Leptin Improves Fatty Liver Independently of Insulin Sensitization and Appetite Suppression in Hepatocyte-Specific Pten-Deficient Mice with Insulin Hypersensitivity. Hormone and Metabolic Research. 47(3). 168–175. 7 indexed citations

Sakai, Takeru, Toru Kusakabe, Ken Ebihara, et al.. (2014). Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet. American Journal of Physiology-Endocrinology and Metabolism. 307(8). E712–E719. 11 indexed citations

Aizawa‐Abe, Megumi, Ken Ebihara, Tomoji Mashimo, et al.. (2013). Generation of leptin-deficient Lep^mkyo/Lep^mkyo rats and identification of leptin-responsive genes in the liver. Physiological Genomics. 45(17). 786–793. 11 indexed citations

10.

Miyamoto, Licht, Ken Ebihara, Toru Kusakabe, et al.. (2012). Leptin Activates Hepatic 5′-AMP-activated Protein Kinase through Sympathetic Nervous System and α1-Adrenergic Receptor. Journal of Biological Chemistry. 287(48). 40441–40447. 63 indexed citations

11.

Satoh, Noriko, Akira Shimatsu, Kazunori Yamada, et al.. (2006). An α-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism. 55(6). 786–793. 32 indexed citations

12.

Masuzaki, Hiroaki, Yoshihiro Ogawa, Megumi Aizawa‐Abe, & Kazuwa Nakao. (2002). Transgenic Approach toward Leptin Biology: The Clinical Implications of Leptin for the Treatment of Obesity-Associated Diabetes and Obesity-Related Hypertension.. Endocrine Journal. 49(2). 109–119. 1 indexed citations

13.

Ogawa, Yoshihiro, Hiroaki Masuzaki, Ken Ebihara, et al.. (2002). Pathophysiogical role of leptin in lifestyle-related diseases. Journal of Diabetes and its Complications. 16(1). 119–122. 11 indexed citations

14.

Shintani, Mitsuyo, Yoshihiro Ogawa, Ken Ebihara, et al.. (2001). Ghrelin, an Endogenous Growth Hormone Secretagogue, Is a Novel Orexigenic Peptide That Antagonizes Leptin Action Through the Activation of Hypothalamic Neuropeptide Y/Y1 Receptor Pathway. Diabetes. 50(2). 227–232. 690 indexed citations breakdown →

15.

Matsuoka, Naoki, Yoshihiro Ogawa, Hiroaki Masuzaki, et al.. (2001). Decreased triglyceride-rich lipoproteins in transgenic skinny mice overexpressing leptin. American Journal of Physiology-Endocrinology and Metabolism. 280(2). E334–E339. 21 indexed citations

16.

Ebihara, Ken, Yoshihiro Ogawa, Hiroaki Masuzaki, et al.. (2001). Transgenic Overexpression of Leptin Rescues Insulin Resistance and Diabetes in a Mouse Model of Lipoatrophic Diabetes. Diabetes. 50(6). 1440–1448. 189 indexed citations

17.

Yura, Shigeo, Yoshihiro Ogawa, Norimasa Sagawa, et al.. (2000). Accelerated puberty and late-onset hypothalamic hypogonadism in female transgenic skinny mice overexpressing leptin. Journal of Clinical Investigation. 105(6). 749–755. 112 indexed citations

18.

Aizawa‐Abe, Megumi, Yoshihiro Ogawa, Hiroaki Masuzaki, et al.. (2000). Pathophysiological role of leptin in obesity-related hypertension. Journal of Clinical Investigation. 105(9). 1243–1252. 397 indexed citations

19.

Masuzaki, Hiroaki, Yoshihiro Ogawa, Megumi Aizawa‐Abe, et al.. (1999). Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal yellow agouti mutation: usefulness of leptin for the treatment of obesity-associated diabetes.. Diabetes. 48(8). 1615–1622. 75 indexed citations

20.

Ebihara, Ken, Yoshihiro Ogawa, Goro Katsuura, et al.. (1999). Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action.. Diabetes. 48(10). 2028–2033. 147 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact